Physician profile
Christopher Hansen
NPI 1447332242
$2,249.94
in general payments reported to CMS, 2019-2025
13 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $492 · 2021: $394 · 2022: $219 · 2023: $265 · 2024: $352 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $675.72 | 2019-2025 | Total30, Precision7, Precision 1 |
| Coopervision INC. | $292.38 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Lkc Technologies, INC. | $220.04 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $203.62 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $183.48 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $168.70 | 2021 | |
| Bausch & Lomb Americas INC. | $156.89 | 2022-2025 | Infuse, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.25 | 2020 | |
| Allergan, INC. | $92.38 | 2021 | |
| Penumbra, INC. | $73.44 | 2019 | |
| Ocular Therapeutix, INC. | $23.54 | 2025 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $17.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.